The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for lisocabtagene maraleucel (liso-cel) for adults with relapsed or ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) significantly increases the risk of developing hepatocellular carcinoma (HCC) in patients with type 2 diabetes, according to results of ...